Intervacc AB (publ) (STO:IVACC)
Sweden · Delayed Price · Currency is SEK 1.142
-0.008 (-0.70%)
Apr 30, 2026, 12:59 PM CET
Intervacc AB Earnings Call Transcripts
Fiscal Year 2026
-
A unique animal vaccine platform is driving rapid growth, with Strangvac for horses showing strong efficacy and expanding into new markets. Piggyvac for pigs targets a large unmet need, and US entry is planned post-2027 via partnerships. Sales surged 300% last year.
Fiscal Year 2025
-
A novel recombinant protein vaccine for strangles in horses has shown strong safety and efficacy, with over 30,000 horses vaccinated in Europe and growing support from veterinarians. Expansion efforts target the U.S. and other major markets, with regulatory approval expected around 2027–2028.